News

The transaction is scheduled to close on April 30, 2008 pending regulatory approval. The acquisition will include the relevant business, customer contracts, associated products, process technology, intellectual property,

The double-blind, randomized, parallel, 16-week study of 1,455 patients with dyslipidemia evaluated flushing symptoms. Across the 16-week treatment period, patients on Cordaptive reported significantly less flushing as measured

These cardiovascular events occurred in 16.66% of patients receiving Micardis (telmisartan) versus 16.46% of patients receiving ramipril. The relative risk (ratio of the probability of the event occurring

Treatment with combination therapy resulted in exceptional blood pressure control at 30 months. Before entering the study, almost all patients were treated with multiple high blood pressure medicines.

In this study, patients taking taranabant 2mg experienced more than double the amount of weight loss at 52 weeks compared to patients treated with placebo. Patients on taranabant

This facility, which will be managed by The Immune Tolerance Institute (ITI) and located initially at Beckman Coulter’s Cellular Analysis Business Group in Miami, will integrate state-of-the-art genomic,

Inlog’s shareholders must use $500,000 of the cash proceeds to purchase Global Med common stock in the open market within three months of the closing. Global Med will

Impax also announced the appointments of Michael Nestor as divisional president reporting to Larry Hsu, president and CEO of IMPAX, and Suneel Gupta, as divisional chief scientific officer

Both TriLipix (ABT-335) studies are part of the largest clinical program to date designed to evaluate the efficacy and safety of a fibrate in combination with statins. These